Check out CYCC - would also benefit from Dacogen approval
Check out CYCC. Trades near cash value and is in phase 3 trial for AML comparing combo of its Sapacitabine + Decitabine vs. Decitabine alone. Has SPA with FDA. In the near term Seliciclib for NSCLC analysis on whether it is effective on k-RAS mutation was promised by year end 2011. And today stock moved up on high volume and no news.
Marxe Austin and Greenhouse don't have any insider info. They dumped for tax loss. Also, they are not known for smart trading in CYCC, for example they sold a large chunk 2 years ago in January just 2-3 days before stock soared.
Anyway, CEO of CYCC just bought at open market. Last time he bought 3 months ago at about the same level and his timing was good.
Much lower market cap for CYCC means more upside in percentage terms than for ASTX. If both drugs - decitabine and sapacitabine would end up been used together in combination therapy, then both companies would have market caps in the same neighborhood, not 3:1 like now.
CYCC has more risk of course because it is earlier stage and cash bleeding